Fig 1: The expression of BMP4 was increased in CRC according to the data from the TCGA database(A) BMP4 expression was investigated in different types of cancer in the TCGA database(B, C) The expression of BMP4 was significantly increased in COAD(B) and READ(C) tumor samples(all P < 0.01) in the TCGA database(D, E) The expression of BMP4 was negatively associated with overall survival probability and disease free survival probability(all p < 0.05)BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin Cutaneous Melanoma; THCA, Thyroid carcinoma; THYM, Thymoma; STAD, Stomach adenocarcinoma; UCEC, Uterine Corpus Endometrial Carcinoma
Fig 2: BMP4 inhibits steatohepatitis and inflammation in FFA-induced hepatocytes.a BMP4 overexpression vector was constructed and expressed in HepG2 and LO2 cells (oe-BMP4) after lentivirus transfection. b Oil red O staining after FFA intervention in oe-BMP4 and control group c Lipid content of TG in oe-BMP4 group and control group after FFA intervention, *p < 0.05. d TG content of noggin added and control group after FFA intervention, *p < 0.05. e Liver transaminase of noggin added and control group after FFA intervention, **p < 0.001. f mRNA levels of inflammatory factors in oe-BMP4 and control group. g mRNA levels of inflammatory factors in noggin added and control group, *p < 0.05, **p < 0.001.
Fig 3: High glucose promoted the proliferation and metastasis of CRC cells(A) Glucose consumption was measured in different types of CRC cell lines by glucose assay kit, *P < 0.05, ***P < 0.001(B) The result of glucose consumption was rectified by cell viability measured by CCK-8 kit (OD 450), *P < 0.05, ***P < 0.001(C) Protein of BMP4 expression examined by western blotting in different types of CRC cell lines(D, E) Treated with high glucose(50mM) 48 h could upregulate the expression of BMP4 measured by western blotting(D) and qRT-PCR(E), *P < 0.05(F) Cell viability of SW1116 and MC38 cultivated by high glucose(50mM) and Noggin(200nM) for 48 h assessed by CCK-8kit, *P < 0.05, ***P < 0.001(G) Transwell assays were performed to examine the potential migration of SW1116 and MC38 cells treated with or without high glucose(50mM) and Noggin(200nM).
Fig 4: BMP4 expression was significantly higher in CRC patients with DM than in CRC patients without DM.(A) The plasma level of BMP4 in CRC patients with DM (CA + DM group) was significantly higher than patients without DM (CA group), *compared to the CA group, P < 0.05(B, C) The upregulation of the protein and RNA expression of BMP4 was confirmed by western blotting and qRT-PCR in CRC specimens from patients with or without DM, *compared to the CA group, P < 0.05(D) Immunohistochemical localization of BMP4 in tumor samples of CRC patients with or without DM (scale bar = 50 μm)
Fig 5: GLP-1RA promoted the apoptosis of CRC cells mediated by the dimmish of BMP4.(A) GLP-1RA promotes the apoptosis of SW1116 examined by flow cytometric analysis(B) Cell viability of SW1116 and MC38 cell lines cultivated by GLP-1RA and recombinant BMP4 for 48 h assessed by CCK-8kit(C) Western blot analysis of the expression of BCL-2, Caspase-3, and cleave-Caspase-3 in SW1116 and MC38 cell lines treated with GLP-1RA and recombinant BMP4.
Supplier Page from Abcam for Recombinant human BMP4 protein (Active)